NYSE:GKOSMedical Equipment
Glaukos (GKOS) Gains Fresh Attention As Trial Progress Keeps Its Valuation Story Alive
Glaukos (GKOS) is back in focus after completing patient enrollment for its Phase 2 GLK-321 trial targeting Demodex blepharitis, a move that coincides with rising expectations around its Epioxa glaucoma franchise.
See our latest analysis for Glaukos.
The GLK-321 update has arrived alongside a sharp pick up in momentum, with Glaukos posting a 1-day share price return of 7.83% and a 30-day share price return of 18.67%. Its 1-year total shareholder return of 46.21% and 3-year total shareholder...